Our Pipeline
Building drug conjugates with multimodal mechanisms of action that provide an impenetrable wall of activity.
Progression towards the clinic by 2025 with a strategy for rapid FIH data acquisition
Programs
Target Validation
Therapeutic Discovery
Preclinical
CO-1008:
Hematologic Tumor
Preclinical
CO-1024:
Solid Tumor
Therapeutic Discovery
CO-1025:
Solid & Hematologic Tumor
Therapeutic Discovery
Various
Solid & Hematologic Tumor
Target Validation
Our Therapeutic Programs
A Franchise of CO-1008 Directed Therapies
Patients with Acute Myeloid Leukemia (AML) currently have few therapeutic options that provide a durable response to tumors. Despite considerable progress in treatment for Non-Hodgkins Lymphoma (NHL), a significant population of Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), and B Cell Acute Lymphoblastic Leukemia (B-ALL) tumors are either CD19-negative or relapse as CD19-negative tumors. CO-1008 aims to resolve this unmet medical need of patients diagnosed with Acute Myeloid Leukemia (AML) or Non-Hodgkins Lymphoma (NHL).
CO-1024: 1st in Class of ADCs to Treat Solid Tumors
Despite considerable progress made in the treatment of Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Gastric Cancer, and Pancreatic Cancers with immune therapy, only a fraction of these patients respond with durable responses. CO-1024-directed ADCs offer a new approach to the treatment of these malignancies with a high unmet medical need.